Efficacy and Safety of Hydrolyzed Ginseng Extract on Impaired Fasting Glucose

An 8 Weeks, Randomized, Double-blind, Placebo-controlled Clinical Trial for Anti-diabetic Effects of Hydrolyzed Ginseng Extract

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01854164

Enrollment

Registered

2013-05-15

Start date

2009-06-30

Completion date

2009-12-31

Last updated

2016-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperglycemia

Keywords

HGE, impaired fasting glucose, clinical trial

Brief summary

This study was conducted to investigate the effects of daily supplementation of hydrolyzed ginseng extract(HGE) on glycemic status in subjects with impaired fasting glucose(IFG).

Detailed description

This study was a 8 weeks, randomized, double-blind, placebo-controlled trial. Twenty subjects were randomly divided into HGE or a placebo group. Fasting and postprandial glucose profiles during oral glucose tolerance test (OGTT) were assessed before and after the intervention.

Interventions

DIETARY_SUPPLEMENTHGE (hydrolyzed ginseng extract)

DIETARY_SUPPLEMENTPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Age 20-70 years with fasting glucose 100\ 126 mg/dL

Exclusion criteria

* Abnormal lipid profile values * Acute/chronic inflammation * Treated with corticosteroid within past 4 weeks * Cardiovascular disease * Allergic or hypersensitive to any of the ingredients in the test products * History of disease that could interfere with the test products or impede their absorption * Participation in any other clinical trials within past 2 months * Renal disease * Abnormal hepatic function * Under hypolipidemic drugs therapy within past 3 months * Under antipsychotic drugs therapy within past 2 months * Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study * History of alcohol or substance abuse * Pregnancy or breast feeding

Design outcomes

Primary

Measure	Time frame	Description
Changes of blood glucose during OGTT(oral glucose tolerance test)	8 weeks	Changes of fasting and postprandial glucose during OGTT were assessed before(baseline) and after the intervention.

Secondary

Measure	Time frame	Description
Changes of blood insulin during OGTT.	8 weeks	Changes of blood insulin during OGTT were assessed before(baseline) and after the intervention.
Changes of glycated albumin, fructosamine, and lipid profile	8 weeks	Changes of glycated albumin, fructosamine, and lipid profile were assessed before(baseline) and after the intervention

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026